Mycelium of Diaporthe nobilis treated with 2% cell-free supernatant (CFS) from Bacillus velezensis A4 for 12 hours

Mycelia of Diaporthe nobilis(50 mg) treated with CFS were collected,Each sample was homogenized in 400 µL of pre-cooled 80% methanol aqueous solution containing 0.02 mg/mL L-2-chlorophenylalanine (internal standard). The mixture was ground and subjected to ultrasonication at 4 °C for 30 min. After centrifugation, the filter supernatants were analyzed using a Thermo UHPLC-Q Exactive system equipped with an ACQUITY HSS T3 column (100 mm × 2.1 mm, 1.8 μm; Waters). Progenesis QI software was used for the analysis and processing of raw LC-MS data. Metabolite identification was performed by comparing with the Human Metabolome Database (HMDB), Metlin, and Majorbio databases. ANOVA, PCA, and OPLS-DA analyses were conducted with seven-cycle cross-validation. Metabolites with Variable Importance (VIP) >1 and eb_eye_copy_status eb_eye_metabolights_compounds.copy eb_eye_metabolights_studies.copy europe_PMC_metabolights_studies.copy europe_PMC_metabolights_studies.xml studies.copy thomsonreuters_metabolights_studies.copy < 0.05 were classified as significantly different metabolites, and functional enrichment analysis was performed based on the KEGG database.